Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Current chemotherapy of human African trypanosomiasis

  • 238 Accesses

  • 79 Citations

Abstract.

Human African trypanosomiasis is a fatal disease caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense that has re-emerged in recent years. However, very little progress has been made in the development of new drugs against this disease. Most drugs still in use were developed one or more decades ago, and are generally toxic and of limited effectiveness. The most recently introduced compound, eflornithine, is only useful against sleeping sickness caused by T. b. gambiense, and is prohibitively expensive for the African developing countries. We present here an overview of today's approved and clinically used drugs against this disease.

This is a preview of subscription content, log in to check access.

Author information

Additional information

Electronic Publication

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Docampo, R., Moreno, S.N. Current chemotherapy of human African trypanosomiasis. Parasitol Res 90, S10–S13 (2003). https://doi.org/10.1007/s00436-002-0752-y

Download citation

Keywords

  • Trypanosoma
  • Fatal Disease
  • Human African Trypanosomiasis
  • Limited Effectiveness
  • Trypanosoma Brucei